Project Grant R01MH136674

Award Date 8/23/24
Completion Date 6/30/29
Dollars Obligated $830K
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This federal Project Grant award, sponsored by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), provides $2,181,744 to The Trustees of the University of Pennsylvania to conduct research on the molecular and circuit mechanisms underlying neurexin1-mediated goal-directed dysfunction. The key objectives of this 5-year research project are to: 1) mechanistically examine how the genetic risk factor neurexin1 contributes to the striatal...
This $632,243 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to understand the molecular and cellular mechanisms of cerebellar dysfunction in neurodevelopmental disorders (NDDs). The primary goal is to elucidate how disruptions to cerebellar inhibitory neurons, particularly Purkinje cells and GABAergic interneurons,...
The National Institute of Mental Health (NIMH) awarded a $911,929 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the Scripps Research Institute in La Jolla, CA on September 5, 2024. The grant will fund a research project titled "Scalable Functional Analysis of Neuropsychiatric Risk Genes with Spatially Integrated In Vivo Perturb-Seq." The project aims to combine high-content in vivo genetic screening with whole brain cytoarchitecture spatial information to bridge the...
The National Institute of Mental Health (NIMH) awarded a $434,421 Project Grant (CFDA 93.242 Mental Health Research Grants) to The Feinstein Institutes for Medical Research to study the development of cerebellar-cortical functional connectivity in youth and its prediction of psychosis. The 4-year grant aims to: Chart the normal development of cerebellar-cortical connectivity from childhood to early adulthood using data from the Lifespan Human Connectome Project in Development. Investigate how...
This Project Grant award, valued at $3,498,931.00, was provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program. The grant funds a comprehensive research initiative called "Cross Scale Interrogation of NPD Genes (SING) in Mice", which aims to investigate the impact of loss of 100 neurodevelopmental and psychiatric disorder (NPD) genes in mice across multiple scales, including gene expression, cellular changes, neural...
This $264,600 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to elucidate the mechanisms underlying CBX1-related syndrome, a neurodevelopmental disorder caused by variants in the CBX1 gene that encodes the heterochromatin protein 1 beta (HP1B). The research objective is to investigate how patient-identified CBX1 variants...
This Project Grant award in the amount of $800,485 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) is supporting research to investigate the role of human-specific 3D genome conformation in brain development and disease. The project aims to analyze the spatial genome organization, particularly topologically associated domains (TADs), in human and primate cortical neural progenitor cells and neurons to identify human-specific TAD...
The National Institute of Neurological Disorders and Stroke (NINDS), part of the Department of Health and Human Services, awarded a $4,528,840 Project Grant to The Salk Institute For Biological Studies under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The three-year award beginning August 19, 2022 will fund research to functionally dissect cerebellar output circuits that orchestrate limb motor control. Specifically, the grantee will...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $605,523 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to The Trustees of Columbia University in the City of New York to support research aimed at developing therapies to restore circuit function in cerebellar degeneration. The research will study a mouse model of cerebellar degeneration to determine how the loss of Purkinje cell synapses contributes to...
The National Institute of Mental Health (NIMH) awarded a $437,250 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the University of Pittsburgh to study the role of local interneurons in early cortical dysfunction in Shank3 knockout mice, a model of autism spectrum disorder (ASD). The grant will fund research using whole-cell electrophysiology and 2-photon microscopy to characterize the physiological properties of Shank3 knockout cortical parvalbumin and somatostatin-positive...

This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $830,168 to The Trustees of the University of Pennsylvania to study the role of the cytoskeletal protein βII-spectrin in the cerebellum and its contribution to neurodevelopmental disorders.

The research aims to define the molecular mechanisms underlying disruption of excitable axonal domains and synaptic transmission in cerebellar granule cells caused by βII-spectrin deficiencies. It will leverage novel transgenic mouse models carrying clinically relevant SPTBN1 variants to assess the effects on cerebellar function and related behaviors. A sub-award of $615,680 has been provided to The Children's Hospital of Philadelphia to conduct electrophysiological recordings from cerebellar neurons in these mouse models. The findings could elucidate how disruptions in the neuronal cytoskeleton contribute to the neurological symptoms observed in individuals with pathogenic SPTBN1 variants.

Generated 7/1/25, 4:20 AM